Cancer can strike anywhere, and tumors of the urinary system deserve early attention. Wandering symptoms often lead to delayed diagnosis of cancers of kidney, cancers of prostate, and cancers of urinary bladder. At Vandana Uro Care, our multi‑disciplinary oncology team emphasizes early detection and comprehensive management.
Kidney cancer frequently presents with blood in urine, flank pain, or a palpable mass. Routine imaging—ultrasound, CT scan, or MRI—confirms diagnosis, while biopsy establishes tumor type. Treatment typically involves partial or radical nephrectomy, sometimes complemented by targeted therapies like tyrosine kinase inhibitors for advanced disease.
Prostate cancer often grows slowly and may remain asymptomatic in the early stages. Elevated prostate‑specific antigen (PSA) levels or an abnormal digital rectal exam trigger further evaluation with MRI and ultrasound‑guided biopsy. Localized tumors respond well to radical prostatectomy, radiation therapy, or active surveillance for low‑risk cases. Hormone therapy and novel immunotherapies expand options for metastatic disease.
Bladder cancer most commonly manifests as painless blood in urine. Cystoscopy allows direct visualization and biopsy of suspicious lesions. Superficial tumors are treated via transurethral resection and intravesical therapy, while invasive cancers may require partial or radical cystectomy along with urinary diversion procedures. Advances in checkpoint inhibitors have improved outcomes for advanced bladder cancers.
Survivorship care is crucial. Regular follow‑up imaging, PSA monitoring, and cystoscopic surveillance detect recurrences early. Our urology‑oncology specialists collaborate closely with radiologists, pathologists, and medical oncologists to craft personalized treatment pathways, minimizing side effects while maximizing efficacy.
If you notice persistent urinary changes or have risk factors—like family history, smoking, or chemical exposure—consult Vandana Uro Care promptly. Timely screening and intervention can significantly improve outcomes for cancers of the kidney, prostate, and urinary bladder.
